Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation Improves Survival in Patients with Multiple Myeloma and End Stage Renal Disease

Sandeep Anand Padala, Anusha Vakiti, Wendy Bollag, Jennifer Waller, Mufaddal Kheda, Stephanie L Baer, Ravindra Kolhe, Mohammad A.H. Mian, Anand P. Jillella, Jorge E. Cortes, Vamsi Kota

Blood (2022) 140 (Supplement 1): 7697–7698.

https://doi.org/10.1182/blood-2022-170672

Published: 2022

Journal Articles

Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITD high but Not FLT3-ITD low and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Eric S. Winer, Yael Flamand, Rory Michael Shallis, Jessica M. Stempel, Aaron D Goldberg, Maximilian F. Stahl, Anand Ashwin Patel, Adam S Duvall, Yasmin Abaza, Timothy Seijung Oh, Karen Ma, Talha Badar, Mark R. Litzow, Vamsi Kota, Danielle Bradshaw, Hari S. Raman, Marlise R. Luskin, Richard M. Stone, Daniel J. DeAngelo

Blood (2022) 140 (Supplement 1): 6285–6287.

https://doi.org/10.1182/blood-2022-170587

Published: 2022

Journal Articles

Optical Genome Mapping and Comprehensive Next Generation Sequencing Panel for Myeloid Cancers: New Era of Complimentary Profiling

Nikhil Sahajpal, Ashis Mondal, Anand P. Jillella, Vamsi Kota, Ravindra Kolhe

Blood (2022) 140 (Supplement 1): 9175–9176.

https://doi.org/10.1182/blood-2022-170638

Published: 2022

Journal Articles

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Blood (2021) 138 (Supplement 1): 1273.

https://doi.org/10.1182/blood-2021-149361

Published: 2021

Journal Articles

Rates of Neutropenic Fever in Patients with Hematologic Malignant Diseases with Central Venous Access

Sujith Abbagoni, Sarah Malik, Ashley D Fox, Mohammad A. H. Mian, Tahsin Anwar, Danielle Bradshaw, Locke J. Bryan, Anand P Jillella, Ravindra Kolhe, Natasha M. Savage, Sandeep Padala, Vamsi Kota

Blood (2021) 138 (Supplement 1): 4953.

https://doi.org/10.1182/blood-2021-154465

Published: 2021

Journal Articles

The Increased Use of Diagnostic Studies over Time in Acute Myelogenous Leukemia Patients

Chijioke Okereke, Ashley D Fox, Thuy Le, Sujith Abbagoni, Anand P Jillella, Locke J. Bryan, Tahsin Anwar, Mohammad A. H. Mian, Vamsi Kota

Blood (2021) 138 (Supplement 1): 4979.

https://doi.org/10.1182/blood-2021-154312

Published: 2021

Journal Articles

Central Line Associated Bloodstream Infection Rate Among Hematologic Malignant Patients Who Received Antimicrobial Prophylaxis in the Inpatient Setting

Sujith Abbagoni, Thuy Le, Locke J. Bryan, Mohammad A. H. Mian, Danielle Bradshaw, Ashley D Fox, Anand P Jillella, Chijioke Okereke, Ravindra Kolhe, Natasha M. Savage, Vamsi Kota

Blood (2021) 138 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2021-154524

Published: 2021

Journal Articles

Serum Albumin As a Prognostic Factor for Overall Survival at 6-Months in Acute Myeloid Leukemia (AML)

Ashley D Fox, Chijioke Okereke, Thuy Le, Anand P Jillella, Locke J. Bryan, Tahsin Anwar, Mohammad A. H. Mian, Danielle Bradshaw, Ravindra Kolhe, Natasha M. Savage, Germame Ajebo, Sandeep Padala, Sujith Abbagoni, Vamsi Kota

Blood (2021) 138 (Supplement 1): 1226.

https://doi.org/10.1182/blood-2021-154138

Published: 2021

Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-139136

Published: 2020

Journal Articles

Racial Variations in Mutational Profile in Newly Diagnosed Acute Myeloid Leukemia Patients

Tahsin Anwar, Mohammed Mian, Mahran Shoukier, Achuta K Guddati, Moinul Hossain, Ravindra Kolhe, MD PhD, Locke J. Bryan, Anand P Jillella, MD, Jorge E. Cortes, MD, Vamsi Kota, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-143329

Published: 2020

Journal Articles

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

Mahran Shoukier, Vamsi Kota, MD, Ravindra Kolhe, MD PhD, Locke J. Bryan, Anand P Jillella, MD, Jorge E. Cortes, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-135940

Published: 2020

Journal Articles

Treatment of Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Using Tyrosine Kinase Inhibitors in Combination with Chemotherapy: A Patient-Centered Benefit-Risk Assessment

Ajibade O Ashaye, MD MBA, MPH, MSc., Caitlin Thomas, MSc, Mehul Dalal, PhD, Vamsi Kota, MD, Nicolas Krucien, PhD, Maria Sae-Hau, PhD, Meredith Barnhart, PhD LCSW-R, OSW-C, Elisa S. Weiss, PhD, Scott Campbell, BSc, Kevin Marsh, PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-137577

Published: 2020

Journal Articles

Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

Jorge E. Cortes, MD, Philipp D le Coutre, MD, Carlo Gambacorti-Passerini, MD, Henrik Hjorth-Hansen, MD, Pia Raanani, MD, Valentín Garcia-Gutiérrez, MD PhD, Vamsi Kota, MD, Simon Purcell, Andrea Viqueira, Eric Leip, Tim H Brümmendorf, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134912

Published: 2020

Journal Articles

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Tim H Brümmendorf, MD, Jorge E. Cortes, MD, Dragana Milojkovic, Carlo Gambacorti-Passerini, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Philipp D le Coutre, MD, Valentín Garcia-Gutiérrez, MD PhD, Charles Chuah, MD, Vamsi Kota, MD, Jeffrey H. Lipton, MD PhD, Philippe Rousselot, MDPhD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Rafael Hurtado Monroy, MD, Eric Leip, Simon Purcell, Anne Yver, PharmD, Andrea Viqueira, MD, Michael W. Deininger, MD PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-137393

Published: 2020

Journal Articles

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Ehab L. Atallah, MD, Islam Sadek, Xiting Cao, Dominick Latremouille-Viau, Irina Pivneva, PhD, Carmine Rossi, Annie Guerin, Vamsi Kota, MBBS

Blood (2019) 134 (Supplement_1): 2208.

https://doi.org/10.1182/blood-2019-125736

Published: 2019

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Jessica K. Altman, Tsila Zuckerman, MD, Olga Frankfurt, MD, Selina M. Luger, MD FRCPC, Dale L. Bixby, MD, Vamsi Kota, MBBS, Micah M. Burch, Ofir Wolach, Itai Levi, MD, Anna Gourevitch, Ron Ram, MD, Liat Flaishon, Shoshi Tessler, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe, MB, BS

Blood (2019) 134 (Supplement_1): 179.

https://doi.org/10.1182/blood-2019-124330

Published: 2019

Journal Articles

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Nabin Karki, MBBS, Vamsi Kota, MBBS, Katherine Saunders, PharmD, Cara Iacobellis, PharmD, Anand Jillella, MD, Germame Ajebo, MD, Locke J. Bryan, MD

Blood (2019) 134 (Supplement_1): 5294.

https://doi.org/10.1182/blood-2019-129644

Published: 2019

Journal Articles

Social Media Network Utility in Disease Education: Experience from a CML-Disease Awareness Medical Education Program

Ehab L. Atallah, MD, Vamsi Kota, MBBS, Islam Sadek, Andrea Damon, PhD, Ji-May Jen, PharmD, Berna Cakmak, BPharm, Joshua Landy, MD FRCPC, Sharon Vorona, MBBS, Jerald P. Radich, MD

Blood (2019) 134 (Supplement_1): 5842.

https://doi.org/10.1182/blood-2019-124809

Published: 2019

Journal Articles

Trends in Crossover of Patients in Phase III Clinical Trials for Hematologic Malignancies

Justin Yeh, BA, Lakshmi Priyanka Pappoppula, MBBS, Vamsi Kota, Anand Jillella, MD, Achuta Kumar Guddati, MD PhD

Blood (2019) 134 (Supplement_1): 5894.

https://doi.org/10.1182/blood-2019-128667

Published: 2019

NARROW

Autologous Hematopoietic Stem Cell Transplantation Improves Survival in Patients with Multiple Myeloma and End Stage Renal Disease

Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITD high but Not FLT3-ITD low and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Optical Genome Mapping and Comprehensive Next Generation Sequencing Panel for Myeloid Cancers: New Era of Complimentary Profiling

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Rates of Neutropenic Fever in Patients with Hematologic Malignant Diseases with Central Venous Access

The Increased Use of Diagnostic Studies over Time in Acute Myelogenous Leukemia Patients

Central Line Associated Bloodstream Infection Rate Among Hematologic Malignant Patients Who Received Antimicrobial Prophylaxis in the Inpatient Setting

Serum Albumin As a Prognostic Factor for Overall Survival at 6-Months in Acute Myeloid Leukemia (AML)

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Racial Variations in Mutational Profile in Newly Diagnosed Acute Myeloid Leukemia Patients

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

Treatment of Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Using Tyrosine Kinase Inhibitors in Combination with Chemotherapy: A Patient-Centered Benefit-Risk Assessment

Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Social Media Network Utility in Disease Education: Experience from a CML-Disease Awareness Medical Education Program

Trends in Crossover of Patients in Phase III Clinical Trials for Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only